2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)-Reference-Cited by-同舟云学术

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Published:2019-12-19 Issue:2 Volume:63 Page:221-228
ISSN:0012-186X
Container-title:Diabetologia
language:en
Short-container-title:Diabetologia

Author:

Buse John B.^ORCID,Wexler Deborah J.^ORCID,Tsapas Apostolos^ORCID,Rossing Peter,Mingrone Geltrude^ORCID,Mathieu Chantal^ORCID,D’Alessio David A.,Davies Melanie J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00125-019-05039-w.pdf

Reference20 articles.

1. Davies MJ, D’Alessio DA, Fradkin J et al (2018) Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41(12):2669–2701. https://doi.org/10.2337/dci18-0033

2. Davies MJ, D’Alessio DA, Fradkin J et al (2018) Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 61(12):2461–2498. https://doi.org/10.1007/s00125-018-4729-5

3. Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 394(10193):121–130. https://doi.org/10.1016/S0140-6736(19)31149-3

4. Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357. https://doi.org/10.1056/NEJMoa1812389

5. Zelniker TA, Wiviott SD, Raz I et al (2019) Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 139(17):2022–2031. https://doi.org/10.1161/CIRCULATIONAHA.118.038868

Cited by 395 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consecuencias de la inadecuada adherencia terapéutica en diabetes mellitus y propuestas de mejora;Atención Primaria Práctica;2024-10

2. Antidiabetic potential of sea fish mass by inhibiting di-peptidyl peptidase-IV and augmenting glucagon-like peptide-1 on high lipid diet and streptozotocin induced diabetic rats;Pharmacological Research - Natural Products;2024-09

3. Glycemic status and effect on mortality: Multifactorial prevention programme for cardiovascular disease in Finnish primary care;Primary Care Diabetes;2024-09

4. Initiation or switch to insulin degludec/insulin aspart in adults with type 2 diabetes in India: Results from a prospective, non-interventional, real-world study;Journal of Family Medicine and Primary Care;2024-09

5. Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-08-21